The potential application of PD-1 blockade therapy for early-stage biliary tract cancer
- 1 April 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 32 (4), 273-281
- https://doi.org/10.1093/intimm/dxz080
Abstract
Biliary tract cancer (BTC) is an aggressive cancer with a poor prognosis partially due to the limited success in developing novel therapies, including molecularly targeted therapies and immunotherapies. Programmed cell death-1 (PD-1) blockade therapy is less effective against BTCs, necessitating further studies to understand the detailed immunological status of the tumor microenvironment (TME) in BTC. Here, we examined the immunological status of the TME in 37 BTCs with early- to late-stage disease, especially focusing on PD-1(+)CD8(+) T cells. PD-1(+)CD8(+) T cells, which are reportedly associated with the clinical response to PD-1 blockade therapy, were frequently observed in early-stage BTC and decreased with disease progression. Imaging mass cytometry for representative PD-1(+)CD8(+)TIL-high and -low patients demonstrated that tumor-infiltrating PD-1(+)CD8(+) T cells were localized adjacent to tumor cells, whereas PD-1(-)CD8(+) T cells were detected mainly in the stroma of the TME. In a mouse model, PD-1 expression by tumor-infiltrating CD8(+) T cells was higher in smaller tumors and decreased with tumor growth. Consequently, large tumors became resistant to PD-1 blockade, while small tumors containing higher numbers of PD-1(+)CD8(+) T cells were sensitive. We propose the important role of tumor-infiltrating PD-1(+)CD8(+) T cells in anti-tumor immunity and the potential application of PD-1 blockade therapy for early-stage BTC.Funding Information
- Grants-in-Aid for Scientific Research
- Japan Agency for Medical Research and Development (16cm0106301h0002, 18cm0106340h0001, 19ae0101074s0401)
- National Cancer Center Research and Development Fund (28-A-7, 31-A-7)
- Naito Foundation
- Takeda Science Foundation
- Ono Pharmaceutical Co. Ltd
- Bristol-Myers Squibb
This publication has 38 references indexed in Scilit:
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and PromotionScience, 2011
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerThe New England Journal of Medicine, 2010
- Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription FactorImmunity, 2009
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- Induction of FOXP3 expression in naive human CD4+FOXP3− T cells by T-cell receptor stimulation is transforming growth factor-β–dependent but does not confer a regulatory phenotypeBlood, 2007
- Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survivalNature Medicine, 2004